Synthesis, Characterization, and in Vitro Activity of Dendrimer−Streptokinase Conjugates
Authors:
- 13 April 2007
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 18 (3) , 791-799
Abstract
Dendrimer conjugation with low molecular weight drugs has been of increasing interest recently for improving pharmacokinetics, targeting drugs to specific sites, and facilitating cellular uptake. Opportunities for increasing the performance of relatively large therapeutic proteins such as streptokinase (SK) using dendrimers are being explored in this study. Using the active ester method, a series of streptokinase−poly(amido amine) (PAMAM) G3.5 conjugates were synthesized with varying amounts of dendrimer-to-protein molar ratios. Characterization of these conjugates by GPC, IEC, and native-PAGE suggested that the conjugation reaction was successful, resulting in relatively pure SK−dendrimer conjugates. The conjugate made with an equimolar ratio of dendrimer to streptokinase (1:1) exhibited the highest enzymatic activity retention (∼80% retained) that has been reported so far for conjugated streptokinase with macromolecules such as PEG or dextran. SK conjugates with higher streptokinase-to-dendrimer molar ratios (1:10 and 1:20) exhibited lower initial enzymatic activities. However, these conjugates showed sustained thrombolytic activity in plasma, perhaps due to the release of SK from the conjugate. All of the SK conjugates displayed significantly improved stability in phosphate buffer solution, compared to free SK. The high coupling reaction efficiencies and the resulting high enzymatic activity retention achieved in this study could enable a desirable way for modifying many bioactive macromolecules with dendrimers.Keywords
This publication has 20 references indexed in Scilit:
- Dendrimers in biomedical applications—reflections on the fieldAdvanced Drug Delivery Reviews, 2005
- Dendrimer biocompatibility and toxicityAdvanced Drug Delivery Reviews, 2005
- Stabilization of a freeze-dried recombinant streptokinase formulation without serum albuminJournal of Clinical Pharmacy and Therapeutics, 2004
- Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymersInternational Journal of Pharmaceutics, 2003
- The influence of surface modification on the cytotoxicity of PAMAM dendrimersInternational Journal of Pharmaceutics, 2003
- Attachment of Degradable Poly(Ethylene Glycol) to Proteins has the Potential to Increase Therapeutic EfficacyJournal of Pharmaceutical Sciences, 1998
- Terminal Groups in Starburst Dendrimers: Activation and Reactions with ProteinsBioconjugate Chemistry, 1998
- Boronated starburst dendrimer-monoclonal antibody immunoconjugates: Evaluation as a potential delivery system for neutron capture therapyBioconjugate Chemistry, 1994
- Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species.Journal of Clinical Investigation, 1984
- Preparation of polyethylene glycol‐modified streptokinase with disappearance of binding ability towards anti‐serum and retention of activityFEBS Letters, 1982